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Abstract 
Invariant natural killer T (iNKT) cells have been shown to play a key role in the 
regulation of immunity in health and disease.  However, iNKT cell responses 
have also been found to influence both rejection and the induction of tolerance 
following transplantation of allogeneic cells or organs.  Although a number of 
mechanisms have been identified that lead to iNKT cell activation, how iNKT 
cells are activated following transplantation remains unknown.  This review 
will attempt to identify potential mechanisms of iNKT cell activation in the 
context of transplantation by applying knowledge garnered from other disease 
situations.  Furthermore, we put forward a novel mechanism of iNKT cell 
activation which we believe may be the dominant mechanism responsible for 
iNKT activation in this setting i.e. bystander activation by IL-2 secreted by 
recently activated conventional T cells. 
3 
 
 
Main Text 
NKT cells represent a small population of T lymphocytes that are reactive to 
lipid antigens, presented in the context of the non-polymorphic MHC-class I 
like molecule, CD1d [1].  Although there appears to be a number of subtypes of 
NKT cells, which can be determined through their T cell receptor (TCR) usage, 
cytokine production, expression of specific surface molecules and reactivity, the 
most extensively characterized are the invariant NKT (iNKT) cells [2].  iNKT 
cells are defined by the expression of a semi-invariant TCR composed of a 
V14-J18 chain associated with V8.2, V7, V2 chains in mice and V24-J18 
associated with V11 in humans [3-5]. The distribution of iNKT cells is varied, 
accounting for 30% of the total T cell population in the liver and <1% in the 
spleen, lymph nodes and blood in mice and at slightly lower levels in humans 
[6, 7].  Although iNKT cells represent a relatively low frequency of T cells, their 
limited TCR diversity means that they respond at high frequency following 
activation.  
 
iNKT cells have been shown to play an important role in health and disease 
being involved in both the induction of immunity to pathogens and 
malignancies in addition to the maintenance of tolerance to self-antigens. For 
example, mice deficient in NKT cells are susceptible to the development of 
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chemically induced tumours, whereas wild-type mice are protected [8].  Indeed, 
these experimental findings correlate with clinical data showing that patients 
with advanced cancer have decreased iNKT cell numbers in peripheral blood 
[9]. In addition, in studies using Non-Obese Diabetic (NOD) mice that develop 
a spontaneous form of type 1 diabetes (T1D) mediated by auto-reactive T cells 
iNKT cells can alter the kinetic of disease onset and severity of disease. In this 
model, such mice have been found to contain reduced numbers of NKT cells 
and either activation or increasing the number of iNKT cells in NOD mice 
affords a degree of protection from T1D [10-12]. 
 
The prototypical iNKT cell agonist is the marine-sponge derived -
galactosylceramide (-GalCer), although a broad spectrum of endogenous and 
exogenous ligands have now been characterised [13-19]. The use of -GalCer 
has provided important insight into how iNKT cell activation can regulate 
immunity and collectively these studies have demonstrated that iNKT cells 
occupy an important immunological niche providing a bridge between the 
innate and adaptive arms of the immune system [2].  For example, iNKT cell 
activation is associated with key steps in ensuring effective immune responses 
through the maturation of dendritic cells, activation of NK cells and B cells, 
enhancing T cell responses and suppression of myeloid-derived suppressor 
cells (MDSC) and IL-10-producing neutrophils [20-29].  Although, many of 
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these mechanisms have been defined using potent iNKT cell agonists, such as 
-GalCer, the intricacies of iNKT cell activation, in the absence of such super-
agonists, have largely been restricted to iNKT cell responses in the context of 
cancer, autoimmunity and pathogenic infections [30-32]. In this review we will 
discuss the mechanisms of iNKT cell activation in these disease situations and 
then relate these potential modes of activation to iNKT cell responses following 
transplantation. 
 
iNKT cells are activated following transplantation 
In mice, the absence of NKT cells does not alter the kinetics of rejection of fully 
MHC mismatched cardiac, skin or islet (placed under the kidney capsule) 
transplants [33-35] which may be due to the potent conventional T cell 
alloimmune response overshadowing any contribution to rejection made by 
iNKT cells.  However, there is ample evidence to suggest that iNKT cells are 
activated and participate in responses to transplanted tissue.  For example, 
iNKT cells have been shown to infiltrate both cardiac and skin allografts prior 
to rejection and have been found in expanded numbers in peripheral lymphoid 
tissue following transplantation [36-38]. Furthermore, an increase in the number 
of CD4+ iNKT cells has been reported in patients undergoing an acute cardiac 
rejection episode compared to those patients with stable transplants [39]. 
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The impact of iNKT cell activation following transplantation  
iNKT cells are not only activated but also influence the ensuing  immune 
response to allografts being either pro-rejection or facilitating the induction of 
tolerance depending on the model studied (Table 1; reviewed in [40]).  For 
example, it has been consistently found that animals deficient in either NKT 
cells or iNKT cells are resistant to the induction of tolerance by 
costimulatory/coreceptor molecule blockade [33, 38, 41].  Importantly the 
adoptive transfer of NKT cells into such mice restores tolerance which is 
dependent on IFN, IL-10 and/or CXCL16 [33, 37, 38, 41, 42].  In addition, iNKT 
cells have proved to be essential for the induction of tolerance to corneal 
allografts and have been demonstrated to prevent graft versus host disease 
(GVHD) in an IL-4 dependent manner [43-45]. 
 
However, following transplantation iNKT cell responses do not always 
promote allograft acceptance as we have shown that the activation of iNKT cells 
can promote the rejection rather than acceptance of skin allografts (Janes SE, 
unpublished observation).  Furthermore, transplantation of islets into the liver 
via the portal vein resulted in the activation of iNKT cells, IFN secretion and 
islet destruction mediated by neutrophils [34, 46].  However, this iNKT cell 
response appears to be unique to intra-liver delivery of islets as the same 
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response was not seen upon islet transplantation under the kidney capsule [34].  
These data may suggest that iNKT cells require a degree of inflammation or 
ischemia to become activated, since Li et al has shown that following ischemia 
reperfusion injury of the kidney iNKT cells are rapidly recruited, produce IFN 
and promote neutrophil recruitment [47]. Furthermore, iNKT cell responses 
may alter depending on the type of transplant carried out, for example, 
following either vascularised (heart) or non-vascularised (skin) grafts, since the 
alloantigen drains to iNKT cells residing in the spleen or axillary lymph nodes, 
respectively.  Since, Doisne et al have shown that NK1.1-iNKT cells resident in 
peripheral lymph nodes preferentially producing IL-17 under inflammatory 
conditions [48].  Moreover, we have shown that iNKT cells produce IL-17 
following skin transplantation and promote graft rejection  (Janes SE & Jones 
ND, manuscript in preparation). However, such iNKT cell responses can be 
manipulated as Oh et al have shown that manipulating iNKT cells to release IL-
10, through multiple injection of -GalCer, can also prolong skin graft survival 
[37]. 
 
In summary, the activation of iNKT cells following transplantation of allogeneic 
cell or tissue transplants can alter the ensuing alloimmune response either 
resulting in enhanced rejection or, more often than not, the facilitation of the 
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induction of tolerance. However, how iNKT cells are activated in this context 
remains incompletely understood. 
 
TCR-mediated activation of iNKT cells 
iNKT cells express a semi-invariant TCR that confers reactivity to glycolipids 
presented in the context of CD1d, which is the most extensively characterised 
mechanism of iNKT cell activation.  However, in response to infection, the 
immune system relies upon a complex network of signals through the 
activation of receptors for pathogen-associated molecular patterns, such as the 
Toll-like receptors (TLRs), expressed on antigen-presentation cells (APC), 
consequently promoting antigen-specific T cell responses [49]. During such 
responses iNKT cells have been shown to respond through the recognition of 
microbial–derived lipid antigens, or through APC-derived cytokines following 
TLR ligation, in combination with and without the presentation of self or 
microbial–derived lipids (Figure 1). 
 
There are several types of bacterial antigens that can directly stimulate iNKT 
cells when bound to CD1d, for example, Sphingomonas spp, Borrelia burgdorferi 
and Leishmania donovani, acting independently of TLR-mediated activation of 
APC [14-17, 50, 51].  Interestingly, the composition of the cell wall of Gram-
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negative S. capsulata which lacks the TLR ligand, lipopolysaccharide (LPS) has a 
combination of immunogenic (e.g. -glucuronosylceramide) and non-
immunogenic glycosphingolipids (e.g. tetrasaccharide-containing 
glycosphingolipids), the balance of which is proposed to determine the immune 
response to infection [15, 16, 52].  
 
iNKT cell have also been shown to be activated during viral infection as De 
Santo et al demonstrated that both NKT (CD1d-/-) and iNKT (J18-/-) cell 
deficient mice were highly susceptible to influenza compared with wild-type 
mice [26].  In this model iNKT cells were found to suppress the expansion of 
MDSC which were expanded in CD1d and J18-/- mice [26].  Importantly, 
although the exactly mechanism of iNKT cell activation was not determined, 
the authors suggest that iNKT cells required TCR-CD1d interactions as the 
adoptive transfer of iNKT cells to J18-/- but not CD1d-/- mice suppressed MDSC 
expansion following infection with PR8 [26]. 
 
In addition to responses to pathogen-derived glycolipids, iNKT cells may 
respond to endogenously produced glycosphingolipids such as 
isoglobotrihexosylceramide (IGb3) and lysophosphatidylcholine (LPC) as well 
as further unidentified self non-glycosphingolipids ligands [18, 19, 53-55].  
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Whilst it appears that in the steady state peripheral iNKT cells are not activated 
by self-glycolipids [56] it has been suggested that TLR signaling attenuates 
alpha-galactosidase A expression (that degrades potential glycolipid antigens) 
resulting in the accumulation and enhanced presentation of self-glycolipids and 
subsequent activation of iNKT cells [57].  This pathway for self-glycolipid 
recognition appears important for NKT activation by pathogens such as 
Salmonella enteric which does not contain agonist glycolipids [58-60].  In such 
instances endogenous glycolipid ligands may be increased which in addition to 
the release of APC-derived cytokines, such as IL-12, results in iNKT cell 
activation [58-61]. 
 
Although iNKT cells have been shown to be involved in both tumour 
immunosurveillance [62, 63] and the control of autoimmunity [12, 64, 65] few 
studies have sought to determine how iNKT cells may be activated in these 
diseases. However, Falcone and colleagues showed that by increasing the 
expression of CD1d on islets (using a -cell promoter) that type 1 diabetes failed 
to develop in NOD mice which was attributed to a recruitment of iNKT cells to 
the islets and biased IL-4 cytokine production [66].  Interestingly, in a model of 
collagen induced arthritis one further pathway of TCR-mediated iNKT cell 
activation has been described in which iNKT cells were found to respond to an 
11 
 
endogenous collagen peptide (PPGANGNPGPAGPPG; mCII707-721) rather than 
to a glycolipid [67]. This peptide was shown to be presented by CD1d and 
resulted in the activation of iNKT cells [67].  Since Lui and colleagues were able 
to successfully demonstrate that mCII707-721 vaccination was able to provide 
benefit in a number of autoimmune diseases (i.e.  antigen-induce airway 
inflammation, collagen-induce arthritis and experimental autoimmune 
encephalitis), it is possible that TCR-mediated iNKT cell activation may be 
required in the context of autoimmune responses [67]. 
 
Taken together these data suggest that following transplantation iNKT cells 
may be activated by glycolipids presented by donor APC or recipient APC that 
have received inflammatory signals resulting in the presentation of self-
glycolipids.  However, there is little evidence to support a role for TCR-
mediated activation of iNKT cells following transplantation.  In fact, Oh et al 
have shown that where iNKT cells were required for prolonged allograft 
survival that this process was not dependent on CD1d expression by the donor 
[37].  We have similarly found that iNKT cells expand in lymph nodes 
following fully allogeneic skin transplantation regardless of whether the donor 
expresses CD1d (Jukes et al, in press).  Furthermore, the transfer of iNKT cells 
into CD1d knockout mice was found to restore iNKT cell mediated graft 
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prolongation suggesting that iNKT cell function in this model was not 
dependent on recognition of glycolipids presented by recipient APC [37].   
 
iNKT cell activation by cytokines 
In contrast to iNKT cell activation through direct TCR-mediated signals, 
following the recognition of glycolipid, iNKT cells can also be directly activated 
by pro-inflammatory cytokines.  iNKT cells constitutively express the IL-12 
receptor and have been shown to respond directly to IL-12 leading to tumour 
clearance [68].  Furthermore, Nagarajan and Kronenberg found that APC 
exposed to Escherichia coli lipopolysaccharides (LPS) resulted in the release of 
IL-12 and IL-18 [69].  NKT cells exposed to both IL-12 and IL-18 produced IFN 
thus amplifying innate-derived signals via TLR to promote immunity [69].  
Furthermore, NKT responses in the context of Mouse Cytomegalovirus 
(MCMV) were shown to be dependent on TLR9 dependent activation of DC 
resulting in the subsequent activation of iNKT cells by IL-12 and IFN[70, 
71].  Importantly, iNKT cell activation and IFN secretion were found to be 
independent of CD1d-glycolipid recognition as iNKT cells were similarly 
activated in the presence of a blocking CD1d mAb or following transfer to 
CD1d-/- hosts. 
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Brigl and colleagues have recently reaffirmed this pathway of activation by 
investigating the dominant signals received by iNKT cells following exposure 
to microbes that contains previously defined iNKT cell ligands (Sphingomonas 
yanoikuyae, Streptococcus pneumoniae) [72].  Interestingly, these studies found 
that following infection iNKT cell activation was dominated by activation 
through the IL-12/STAT-4 pathway rather than through TCR mediated 
recognition [72].  
 
The process of transplantation results in surgical trauma and ischemia 
reperfusion injury that results in the activation of DC and the expression of 
proinflammatory cytokines [73].  Indeed transplantation has been shown to be 
accompanied by the release of a number of endogenous TLR ligands such as 
heat shock proteins and oligosaccharides of hyaluronan that can result in TLR4 
dependent DC maturation [74, 75].  Therefore, the transplantation process itself 
may result in the activation of iNKT cells by IL-12/IL-18/IFN/ following TLR 
ligation of APC.  However, although no study to date has addressed this 
possibility directly, we and others have shown that iNKT cells expand in the 
draining lymph node following allogeneic but not syngeneic transplantation 
(Jukes et al, in press; [37]).  Furthermore, iNKT cells were found to only have 
infiltrated allogeneic and not syngeneic skin and heart transplants (Figure 2; 
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data not shown).  We would argue that if iNKT cells were activated after 
transplantation by pro-inflammatory cytokines either directly or in combination 
with self-glycolipid recognition then activation should have been evident after 
syngeneic transplantation.  This does not rule out the impact of innate derived 
signals in shaping the ensuing iNKT cell response but only that it is unlikely to 
be the primary driving force behind iNKT cell activation following 
transplantation. 
 
Bystander iNKT cell activation during adaptive immune responses 
We and others have been able to reveal that iNKT cells are activated following 
transplantation of allogeneic tissue.  This led us to question whether iNKT cells 
may receive activating signals from the adaptive as well as the innate immune 
system.  Although, iNKT cells died when cultured with allogeneic stimulator 
cells we found that the addition of conventional alloreactive T cells to such 
cultures resulted in iNKT cell activation, proliferation and cytokine production 
both in vitro and in vivo (Jukes et al, in press).  The mechanism of iNKT cell 
activation was independent of TCR recognition but rather operated through the 
sequestration of IL-2 derived from activated T cells (Jukes et al, in press). 
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This study now provides a further pathway by which iNKT cells may be 
activated following transplantation (as well as in the context of cancer 
immunosurveillance and autoimmunity).  This highlights the potential of iNKT 
cells to aid in the process of tolerance or rejection and taken together with our 
recent data may suggest that the adaptive immune response could simply ‘tap’ 
into the reservoir of iNKT cell-derived cytokines, to aid in the successful 
generation of either anti- or pro-inflammatory immune responses.  
 
Although IL-2 may activate iNKT cells, clearly the already described innate 
environmental cues may influence the subsequent behaviour of iNKT cells in 
terms of expansion and cytokine production.  Therefore conditions that lead to 
allograft tolerance may promote the expansion of iNKT cells with suppressive 
potential such as the recently described Foxp3+ [76] or IL-10 producing [41] 
iNKT cells.  In particular iNKT cells and Treg may unite in depleting the 
microenvironment of IL-2, encouraging the production of anti-inflammatory 
cytokines (such as IL-10, TGF) thereby promoting allograft survival (Figure 3).  
Alternatively, if iNKT cells respond to IL-2 under pro-inflammatory conditions 
then immunity may be amplified by the secretion of pro-inflammatory 
cytokines by iNKT cells (Figure 3). 
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Can iNKT cells aid transplant tolerance?  
Since transplant patients remain on life-long immunosuppression to prevent 
immune mediated rejection it is important to explore multiple avenues of 
research that may release such a burden of global immunosuppression, whilst 
maintaining graft function.  Our interest in iNKT cells is to understand not only 
how they are involved in the immune response to allografts but also how they 
may be used as a therapeutic ‘stepping-stone’ to tolerance.  Although, many 
new synthetic iNKT cell  agonists have been described which could be used to 
amplify iNKT cell responses following transplantation the factors that govern 
whether iNKT cell activation may promote or attenuate the induction of 
tolerance are incompletely defined. Understanding not only how iNKT cells are 
activated but also how accessory signals integrate to dictate the class and 
strength of the iNKT cell response will be critical in aiding the development of 
potential therapeutic strategies involving the manipulation of these cells.  
Although, there are many questions remaining regarding iNKT cell responses 
following transplantation, dissecting how iNKT cells respond in different 
microenvironments may allow us to ‘tap’ into the potential ability of iNKT cells 
to amplify pathways that promote tolerance.   
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A 
B 
Species Transplant Tolerance Regimen Mechanism of action Ref. 
Mice Islet None 
 
None 
 
Rapamycin 
IFN production promotes PMN 
recruitment to graft 
Islet destruction only found when 
Islets injected into portal vein 
Not determined 
[46] 
 
[34] 
 
[34] 
Mice Skin Anti-CD4, CD8, 
CD154 mAb 
Not determined * 
Mice Skin None Induction of a Th17 response ** 
 
Table. 1 Summary of the involvement of iNKT cells in transplant tolerance (A) 
and rejection (B). It should be noted that in one study in Islet transplantation 
iNKT cells were not shown to contribute to either transplant tolerance or 
rejection [35]. GvHD = Graft versus host disease. *Jukes J-P, Zhao Z and Jones ND 
unpublished observations. ** Janes SE and Jones ND, manuscript in preparation. 
 
 
Species Transplant Tolerance Regimen Mechanism of action Ref. 
Mice Heart Anti-LFA-1/ICAM-1 
or Anti-B7-1/B7-2 
Anti-CD154 mAb 
 
Anti-CD154 mAb 
IFN production? 
 
iNKT cells require CXCL16/CXCR6 
interactions to traffic to allograft 
IL-10 production 
[33] 
 
[38] 
 
[41] 
Mice Skin None IL-10 production [37] 
Mice Heart Anti-CD4, CD8, 
CD154 mAb 
Not determined * 
Mice Islet (rat xenograft) Anti-CD4 mAb IFN production but the dose of 
CD4 is critical for tolerance 
induction. 
[42] 
Mice Cornea None Enhanced regulatory T cell 
function 
[43] 
Mice Bone Marrow None Prevent  GvHD.  IL-4 dependent. [44, 
45] 
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Figure 1. iNKT cells can become activated through a number of directly 
or indirect pathways.  The ‘direct’ pathway acts through the recognition of 
synthetic or microbial ligands presented in the context of CD1d. In contrast the 
‘indirect’ pathways relies upon the release of cytokines from antigen presenting 
cells (APC) that have been activated through TLR ligation in the presence or 
absence of recognition of CD1d-self-glycolipid complexes. In addition, iNKT 
cell-APC interactions can be influenced by ligation of a number of co-
stimulatory molecules, for example, CD28, CD40L, OX40, GITR, ICOS, 41BB 
(CD137). 
 
Figure 2.   iNKT cells are recruited to allogeneic but not syngeneic skin and 
heart grafts in multiple mouse strain combinations. CBA (syngeneic) or 
C57BL/10 (allogeneic) skin grafts were analysed by quantitative real-time PCR 
(qRT-PCR) for V14J18 mRNA expression (to quantify the infiltration of iNKT 
cells) on day 3, 5 and 10 post transplant (A). In addition, heart grafts taken from 
B6 (H2b) recipients of either syngeneic (C57BL/6) or allogeneic (BALB/c) grafts 
were analysed for the expression of V14J18 mRNA on day 1, 3 and 5 post 
transplant (B). Results are expressed as mRNA (Units/HPRT) with naïve skin or 
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heart used to give baseline expression. n=3 per time point. All error bars indicate 
mean ± standard deviation.*p=<0.05. 
 
Figure 3. Mechanisms by which iNKT cells are activated following 
transplantation.  iNKT cells have been implicated in both the induction of 
transplantation tolerance and rejection although the mode of activation remains 
largely unknown.  We have recently described a novel mechanism of bystander 
iNKT cell activation following sequestration of IL-2 produced by activated 
conventional T cells (dotted black arrow). This pathway of activation is 
independent of CD1d-glycolipid/TCR interactions and is associated with the 
production of effector cytokine release (i.e IFN).  We hypothesis that IL-2 
mediated iNKT cell activation may be important in creating a 
microenvironment that promotes transplant tolerance, as Treg and iNKT cells 
may synergistically act to deplete IL-2 from the local microenvironment in 
addition to suppressing alloreactive T cell responses via the release of anti-
inflammatory cytokines and/or interaction with APC bearing alloantigen. It is 
conceivable that such responses may be further enhanced through iNKT cell-
APC interactions via cytokine production (i.e. IL-12) and co-stimulatory 
molecules (CD28, CD40L, OX40, GITR, ICOS, 41BB). 
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